- Home
- NTRA
NTRA
Natera Inc.
as 11-25-2025 3:37pm EST
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
| Founded: | 2003 | Country: | United States |
| Employees: | N/A | City: | AUSTIN |
| Market Cap: | 27.0B | IPO Year: | 2015 |
| Target Price: | $224.88 | AVG Volume (30 days): | 1.8M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 16 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.29 | EPS Growth: | N/A |
| 52 Week Low/High: | $125.38 - $240.40 | Next Earning Date: | 11-06-2025 |
| Revenue: | $2,116,676,000 | Revenue Growth: | 38.17% |
| Revenue Growth (this year): | 25.7% | Revenue Growth (next year): | 15.42% |
Stock Insider Trading Activity of Natera Inc. (NTRA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Sheena Jonathan | NTRA | Director, Other | Nov 11 '25 | Sell | $208.03 | 1,500 | $311,933.77 | 25,282 | |
| Sheena Jonathan | NTRA | Director, Other | Nov 7 '25 | Sell | $194.12 | 3,070 | $591,159.28 | 25,282 | |
| Rabinowitz Matthew | NTRA | EXECUTIVE CHAIRMAN | Nov 4 '25 | Sell | $200.73 | 22,900 | $4,591,674.04 | 2,286,554 | |
| Moshkevich Solomon | NTRA | PRESIDENT, CLINICALDIAGNOSTICS | Nov 3 '25 | Sell | $198.96 | 3,000 | $595,810.04 | 112,161 | |
| Rabinowitz Matthew | NTRA | EXECUTIVE CHAIRMAN | Nov 3 '25 | Sell | $200.00 | 17,100 | $3,420,003.42 | 2,286,554 | |
| Sheena Jonathan | NTRA | Director, Other | Nov 3 '25 | Sell | $200.07 | 4,000 | $800,273.60 | 25,282 | |
| Chapman Steven Leonard | NTRA | CEO AND PRESIDENT | Nov 3 '25 | Sell | $199.00 | 160,703 | $32,133,980.76 | 303,304 | |
| Marcus Gail Boxer | NTRA | Director | Nov 3 '25 | Sell | $198.71 | 122 | $24,242.62 | 5,762 | |
| Brophy Michael Burkes | NTRA | CHIEF FINANCIAL OFFICER | Oct 29 '25 | Sell | $190.35 | 1,867 | $355,924.59 | 65,693 | |
| Moshkevich Solomon | NTRA | PRESIDENT, CLINICALDIAGNOSTICS | Oct 28 '25 | Sell | $191.46 | 1,198 | $229,371.36 | 112,161 |
Latest Natera Inc. News
NTRA Breaking Stock News: Dive into NTRA Ticker-Specific Updates for Smart Investing
StockStory
4 days ago
Natera, Amneal, Chemed, The Pennant Group, and HCA Healthcare Shares Are Soaring, What You Need To Know
GuruFocus.com
5 days ago
Cathie Wood Targets New Tech Winners, Dumps AMD in Major Shuffle
Simply Wall St.
6 days ago
Is Flatiron Health Integration Expanding Natera's Market Opportunity and Investment Narrative for NTRA?
StockStory
6 days ago
Spotting Winners: Natera (NASDAQ:NTRA) And Immuno-Oncology Stocks In Q3
Business Wire
6 days ago
Employees Volunteer Over 1,500 Hours During Natera’s Annual Volunteer Month
MT Newswires
7 days ago
UBS Adjusts Natera Price Target to $280 From $218, Maintains Buy Rating
Business Wire
11 days ago
Liberty All-Star® Growth Fund, Inc. October 2025 Monthly Update
GuruFocus.com
11 days ago
Stanley Druckenmiller's Strategic Moves: Exiting Philip Morris International Inc with a -3. ...
Compare NTRA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NTRA Natera Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.